惠泰医疗: 第二届监事会第十九次会议决议公告

Group 1 - The company announced the invalidation of part of the granted but unvested restricted stock from the 2021 incentive plan, which was deemed compliant with relevant laws and regulations, ensuring no harm to the company or shareholders [1][2] - The Supervisory Board unanimously agreed to the invalidation of the unvested restricted stock, with a voting result of 3 in favor, 0 against, and 0 abstentions [2] - The company confirmed that the conditions for the third vesting period of the B-class restricted stock under the 2021 incentive plan have been met, allowing the grant of 188,237 shares at a price of RMB 123.56 per share to 309 eligible participants [2]